UPAR and cathepsin B shRNA impedes TGF-b1-driven proliferation and invasion of meningioma cells in a XIAP-dependent pathway

Cell Death and Disease

Volumn 3, Issue 12, 2012, Pages

  Gogineni, V R ^a   Gupta, R ^a   Nalla, A K ^a   Velpula, K K ^a   Rao, J S ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

meningioma; shRNA; TGF 1; uPAR and cathepsin B; XIAP

Indexed keywords

CATHEPSIN B; GELATINASE A; GELATINASE B; SHORT HAIRPIN RNA; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; UROKINASE; UROKINASE RECEPTOR; X LINKED INHIBITOR OF APOPTOSIS;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CELL PROLIFERATION; GENE OVEREXPRESSION; GENE SILENCING; MENINGIOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL;

CATHEPSIN B; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MENINGEAL NEOPLASMS; MENINGIOMA; NEOPLASM INVASIVENESS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSFORMING GROWTH FACTOR BETA1; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

ANIMALIA;

EID: 84871234236     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2012.170     Document Type: Article

References (40)

1. Louis DN, Scheithauer BW, Budka H, von Deimling A, Kepes JJ. Meningiomas pathology and genetics of tumours of the nervous system. In: Kleihues P, Cavenee WK (eds). World Health Organization Classification of Tumours. IARC Press: Lyon, 2000. pp 176-184.
2. Jeon SH, Chae BC, Kim HA, Seo GY, Seo DW, Chun GT et al. Mechanisms underlying TGF-beta1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesis. J Leukoc Biol 2007; 81: 557-566.
3. Muraoka RS, Dumont N, Ritter CA, Dugger TC, Brantley DM, Chen J et al. Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. J Clin Invest 2002; 109: 1551-1559.
4. Pepper MS. Transforming growth factor-beta: vasculogenesis, angiogenesis, and vessel wall integrity. Cytokine Growth Factor Rev 1997; 8: 21-43.
5. Ivanovic V, Demajo M, Krtolica K, Krajnovic M, Konstantinovic M, Baltic V et al. Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 2006; 371: 191-193.
6. Kajdaniuk D, Marek B, Swietochowska E, Ostrowska Z, Glogowska-Szelag J, Kos-Kudla B et al. Plasma transforming growth factor beta1 in breast cancer patients treated with CMF chemotherapy. J Clin Pharm Ther 2000; 25: 291-294.
7. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol 2005; 23: 2078-2093.
8. Huang A, Jin H, Wright JA. Drug resistance and gene amplification potential regulated by transforming growth factor beta 1 gene expression. Cancer Res 1995; 55: 1758-1762.
9. Bandyopadhyay A, Agyin JK, Wang L, Tang Y, Lei X, Story BM et al. Inhibition of pulmonary and skeletal metastasis by a transforming growth factor-beta type I receptor kinase inhibitor. Cancer Res 2006; 66: 6714-6721.
10. Caja L, Bertran E, Campbell J, Fausto N, Fabregat I. The transforming growth factor-beta (TGF-beta) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells. J Cell Physiol 2011; 226: 1214-1223.
11. Wilkes MC, Mitchell H, Penheiter SG, Dore JJ, Suzuki K, Edens M et al. Transforming growth factor-beta activation of phosphatidylinositol 3-kinase is independent of Smad2 and Smad3 and regulates fibroblast responses via p21-activated kinase-2. Cancer Res 2005; 65: 10431-10440.
12. Mignatti P, Rifkin DB. Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 1993; 73: 161-195.
13. Rabbani SA, Mazar AP. The role of the plasminogen activation system in angiogenesis and metastasis. Surg Oncol Clin N Am 2001; 10: 393-415.
14. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB, Verspaget HW. Urokinase receptor and colorectal cancer survival. Lancet 1994; 344: 401-402.
15. Lund LR, Ellis V, Ronne E, Pyke C, Dano K. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549. Biochem J 1995; 310: 345-352.
16. Van Themsche C, Chaudhry P, Leblanc V, Parent S, Asselin E. XIAP gene expression and function is regulated by autocrine and paracrine TGF-beta signaling. Mol Cancer 2010; 9: 216 216.
17. Joshi A, Cao D. TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. Front Biosci 2010; 15: 180-194.
18. Kelly RJ, Morris JC. Transforming growth factor-beta: a target for cancer therapy. J Immunotoxicol 2010; 7: 15-26.
19. Bierie B, Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-520.
20. McKarns SC, Letterio JJ, Kaminski NE. Concentration-dependent bifunctional effect of TGF-beta 1 on immunoglobulin production: a role for Smad3 in IgA production in vitro. Int Immunopharmacol 2003; 3: 1761-1774.
21. Cordeiro MF, Bhattacharya SS, Schultz GS, Khaw PT. TGF-beta1,-beta2, and-beta3 in vitro: biphasic effects on Tenon's fibroblast contraction, proliferation, and migration. Invest Ophthalmol Vis Sci 2000; 41: 756-763.
22. Rao JS. Molecular mechanisms of glioma invasiveness: the role of proteases. Nat Rev Cancer 2003; 3: 489-501.
23. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM. TGF-beta-induced invasiveness of pancreatic cancer cells is mediated by matrix metalloproteinase-2 and the urokinase plasminogen activator system. Int J Cancer 2001; 93: 204-211.
24. Chen HH, Zhao S, Song JG. TGF-beta1 suppresses apoptosis via differential regulation of MAP kinases and ceramide production. Cell Death Differ 2003; 10: 516-527.
25. Kim ES, Kim MS, Moon A. TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 2004; 25: 1375-1382.
26. Gupta R, Rao GV, Nalla AK, Chetty C, Klopfenstein JD, Tsung AJ et al. Oncogenic role of p53 is suppressed by si-RNA bicistronic construct of uPA, uPAR and cathepsin-B in meningiomas both in vitro and in vivo. Int J Oncol 2011; 38: 973-983.
27. Ellison DW, Lunec J, Gallagher PJ, Steart PV, Jaros E, Gatter KC. Accumulation of wildtype p53 in meningiomas. Neuropathol Appl Neurobiol 1995; 21: 136-142.
28. Cmielova J, Rezacova M. p21Cip1/Waf1 protein and its function based on a subcellular localization [corrected]. J Cell Biochem 2011; 112: 3502-3506.
29. Leivonen SK, Kahari VM. Transforming growth factor-beta signaling in cancer invasion and metastasis. Int J Cancer 2007; 121: 2119-2124.
30. Hayashida T, Decaestecker M, Schnaper HW. Cross-talk between ERK MAP kinase and Smad signaling pathways enhances TGF-beta-dependent responses in human mesangial cells. FASEB J 2003; 17: 1576-1578.
31. Zhu X, Wang L, Zhang B, Li J, Dou X, Zhao RC. TGF-beta1-induced PI3K/Akt/NF-kappaB/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts. J Biochem 2011; 149: 405-414.
32. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-584.
33. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG et al. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 2004; 279: 5405-5412.
34. ten Dijke P, Arthur HM. Extracellular control of TGFbeta signalling in vascular development and disease. Nat Rev Mol Cell Biol 2007; 8: 857-869.
35. Nunes I, Shapiro RL, Rifkin DB. Characterization of latent TGF-beta activation by murine peritoneal macrophages. J Immunol 1995; 155: 1450-1459.
36. Gondi CS, Lakka SS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M et al. Adenovirusmediated expression of antisense urokinase plasminogen activator receptor and antisense cathepsin B inhibits tumor growth, invasion, and angiogenesis in gliomas. Cancer Res 2004; 64: 4069-4077.
37. Gupta R, Nalla AK, Gogineni VR, Chetty C, Bhoopathi P, Klopfenstein JD et al. uPAR/cathepsin B overexpression reverse angiogenesis by rescuing FAK phosphorylation in uPAR/cathepsin B down regulated meningioma. PLoS One 2011; 6: e17123.
38. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M et al. Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004; 23: 4681-4689.
39. Gondi CS, Lakka SS, Yanamandra N, Siddique K, Dinh DH, Olivero WC et al. Expression of antisense uPAR and antisense uPA from a bicistronic adenoviral construct inhibits glioma cell invasion, tumor growth, and angiogenesis. Oncogene 2003; 22: 5967-5975.
40. McCutcheon IE, Friend KE, Gerdes TM, Zhang BM, Wildrick DM, Fuller GN. Intracranial injection of human meningioma cells in athymic mice: an orthotopic model for meningioma growth. J Neurosurg 2000; 92: 306-314.